Phase II Randomized Study of Selective Dorsal Rhizotomy and Physiotherapy Vs Physiotherapy Alone for Spastic Diplegia
NCT ID: NCT00004751
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
INTERVENTIONAL
1991-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
I. Assess the efficacy and safety of selective dorsal rhizotomy and physiotherapy compared with physiotherapy alone in improving gross motor function and reducing spasticity in children with spastic diplegia.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients are randomly assigned to surgery plus intensive physical therapy versus intensive physical therapy alone.
The surgical procedure is a selective dorsal rhizotomy. Physical therapy (PT) includes passive and active range of motion, facilitation of isolated muscle control, transitional movements, strengthening, transfer skills, and gait training. The PT schedule is 2-hour sessions 5 days a week for 1 month, 1-hour sessions 5 days a week for 5 months, then a standard therapy program for the remainder of the study (total of 6 months). Parents supervise exercise on non-PT days.
Patients are followed at 6, 12, and 24 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Surgery
Physical therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
--Disease Characteristics--
* Spastic diplegia, i.e.: Measurable spasticity with more lower than upper limb involvement
* Fair to good trunk and head control
* Little or no bulbar involvement
* Able to walk or has potential to walk indoors with assistive devices
* No fixed musculoskeletal deformity greater than 15 degrees
* Prior orthopedic surgery acceptable if spastic muscle group is in physiologic biomechanical position and retains voluntary power
* No detectable athetosis, rigidity, ataxia, or other movement disorder
* No disease-related, treatable condition that may become urgent during study, e.g., hip subluxation requiring adductor release
--Patient Characteristics--
* Age: 3 to 18
* Other: Intelligence Quotient greater than 50 Developmental age 3 years or higher
* Able to follow multi-step commands
* Expressive communication skills at 3-year level or higher
* Mild dysarthria or drooling does not exclude
* Stable social environment
* Regular school and physical therapy attendance
* Normal psychiatric status
* Guardian able to give support and follow-up care
* No medical contraindication to anesthesia or surgery, e.g.: Previous anesthesia reaction
* Chronic lung disease
* Uncontrollable seizures
* Scoliosis Vertebral anomaly
* Neural tube defect
* No visual impairment sufficient to hinder mobility
* Able to come to Children's Hospital and Medical Center for follow-up Insurance coverage adequate for surgery and postoperative physiotherapy
3 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seattle Children's Hospital
OTHER
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John F. McLaughlin
Role: STUDY_CHAIR
Seattle Children's Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHS-01699211
Identifier Type: -
Identifier Source: secondary_id
199/11667
Identifier Type: -
Identifier Source: org_study_id